Comparison

Retatrutide vs Tirzepatide

Medically reviewed by Marko Maal · May 7, 2026

Reviewed by Marko Maal, MSc Pharmacy · University of Tartu · Pharmaceutical sciences — drug sourcing, formulation, regulatory review · Reviewed May 7, 2026

Reviewed for clinical and pharmacological accuracy by Marko Maal, MSc Pharmacy.

Dimension	Retatrutide	Tirzepatide
Mechanism	Triple agonist: GLP-1 + GIP + glucagon receptors	Dual agonist: GLP-1 + GIP receptors
FDA status	Investigational — Phase 3 ongoing, no NDA filed	Approved — Mounjaro (T2D) + Zepbound (obesity, OSA)
Mean weight loss (48-72w)	~24% (TRIUMPH-1, Phase 3)	~22.5% (SURMOUNT-4, 88w)
Glucagon effect	Increases energy expenditure, may prevent metabolic slowdown	None — GLP-1 monotherapy can reduce REE over time
Half-life	~6 days (weekly dosing)	~120 hours (~5 days, weekly dosing)
Liver fat reduction	Significant reduction shown in MASH/NAFLD trials	Significant reduction shown (SYNERGY-NASH)
Most common AEs	Nausea (33-45% dose-dependent), diarrhea (25%), vomiting (20%)	Nausea (33%), diarrhea (23%), constipation (17%)
Dose escalation	2 → 4 → 8 → 12 mg weekly	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly
Estimated availability	FDA filing expected H2 2026; possible approval 2027	Available now
Likely cash price	Unknown — expected premium to Zepbound	~$1,060/mo (Zepbound)

How do they actually differ?

Evidence tier: 1 for tirzepatide pharmacology; Tier 2 for retatrutide — Phase 2 NEJM data plus topline Phase 3 readouts as of mid-2026.

Tirzepatide is a dual agonist of the GLP-1 and GIP receptors. Retatrutide adds a third pathway: glucagon receptor agonism, on top of the same GLP-1 and GIP backbone. The mechanistic rationale for adding glucagon is that GLP-1 monotherapy reduces resting energy expenditure over time as patients lose weight — a metabolic adaptation that drives plateau and post-discontinuation regain. Glucagon receptor agonism increases hepatic glucose production and energy expenditure, partially offsetting the slowdown. Both agents are weekly subcutaneous injections with similar half-lives (~5-6 days). Tirzepatide titrates 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg; retatrutide titrates 2 → 4 → 8 → 12 mg in the published Phase 3 design. Both produce dose-dependent gastrointestinal adverse events as the dominant side-effect category. Retatrutide's added glucagon arm carries theoretical risks around hepatic glucose handling, heart rate elevation, and potential for more pronounced lipolysis — these are being characterized in the TRIUMPH program. Tirzepatide is FDA-approved and on pharmacy shelves; retatrutide is investigational. The matrix has dosing, half-life, and Phase 2/3 numbers.

Who should choose retatrutide?

Evidence tier: 5 — speculative until FDA approval. No retatrutide patient should choose it outside a clinical trial in 2026.

Retatrutide is currently available only through clinical trial enrollment. Eli Lilly's TRIUMPH Phase 3 program covers obesity without T2D (TRIUMPH-1), with T2D (TRIUMPH-2), with cardiovascular disease (TRIUMPH-3), and with knee osteoarthritis (TRIUMPH-4). The patient profile likely to benefit most once retatrutide is approved: those who plateaued on tirzepatide despite full-dose maintenance, those with very high BMI where every additional percentage point of weight loss matters clinically, those with comorbid metabolic dysfunction-associated steatohepatitis (MASH) where the glucagon arm may contribute additional liver-fat reduction, and those whose primary clinical concern is the post-discontinuation regain pattern (because preserved resting energy expenditure may dampen regain). None of these is yet supported by retatrutide outcome data; all are mechanistic predictions based on Phase 2 results. Outside of a clinical trial, the practical answer in 2026 is that no patient should choose retatrutide — it isn't legally available. Discuss any consideration of investigational GLP-1-class agents with your physician.

Who should choose tirzepatide?

Evidence tier: 1 — FDA-approved with multi-trial Phase 3 evidence; SURMOUNT and SURPASS programs are mature.

Tirzepatide is the right choice for essentially all patients in 2026 who want a GIP-containing agent because it is the only one approved. SURMOUNT-1 produced 16-22.5% weight loss across doses; SURMOUNT-4 demonstrated continued weight loss through 88 weeks of treatment with substantial regain on placebo withdrawal; SURPASS-2 demonstrated superiority to semaglutide on A1c and weight in T2D. Zepbound carries the FDA indication for moderate-to-severe obstructive sleep apnea in obesity (December 2024), which is a unique advantage in the class. Patients with T2D, with obesity, with OSA, with MASH, or with any combination should consider tirzepatide as the default GIP-containing agent. The titration from 2.5 mg to a maintenance dose typically completes in 4-5 months, with most patients reaching effective weight loss at 7.5-15 mg weekly. Insurance coverage has expanded substantially post-Zepbound and post-OSA. Patients on tirzepatide who plateau, tolerate the drug well, and want additional weight loss are also reasonable candidates to wait for retatrutide approval rather than switching to a different mechanism. Discuss the indication match with your physician.

What does the evidence base actually say?

Evidence tier: 1 for tirzepatide; Tier 2 for retatrutide — published NEJM Phase 2 plus Phase 3 topline.

Tirzepatide has the deeper evidence base because it has been on the market since 2022. The SURMOUNT program covers obesity with and without T2D (SURMOUNT-1, -2), maintenance (SURMOUNT-4), head-to-head versus semaglutide (SURMOUNT-5), and OSA (SURMOUNT-OSA). The SURPASS program covers T2D across multiple comparators including semaglutide (SURPASS-2). The cardiovascular outcomes trial (SURPASS-CVOT) is ongoing with readout expected 2027. Retatrutide has one Phase 2 trial published in NEJM (Jastreboff 2023): 338 adults randomized to retatrutide 1, 4, 8, 12 mg or placebo, with the 12 mg arm achieving 17.5% weight loss at 24 weeks — a steeper trajectory than tirzepatide showed at the same timepoint. The Phase 3 TRIUMPH program is ongoing, with topline results pointing to ~24% weight loss at 48-72 weeks — modestly higher than tirzepatide's ~22% in SURMOUNT-1/4 at similar timepoints. There is no head-to-head retatrutide-versus-tirzepatide trial. The best evidence currently available is indirect comparison via cross-trial data, which suggests retatrutide produces deeper weight loss but is not yet sufficient for regulatory or insurance comparison.

Cost, access, and regulatory comparison

Evidence tier: 2 — FDA status and pricing reflect April 2026 reality and are subject to change as TRIUMPH data matures.

Tirzepatide is FDA-approved as Mounjaro (T2D, 2022), Zepbound (obesity, 2023), and Zepbound for OSA (December 2024). US list price is ~$1,060/month for Zepbound; insurance coverage is increasingly common in T2D, OSA, and obesity-with-comorbidity. Lilly's direct-pay program runs at meaningful discounts to list. Retatrutide is investigational. Lilly has not yet filed an NDA; FDA filing is expected in H2 2026 based on company guidance, with possible approval in 2027. There is no public list price. Compounded retatrutide is illegal in the US — the 503A and 503B compounding categories require an FDA-approved reference drug. Any "research-grade retatrutide" sold by international suppliers exists outside both the FDA framework and any quality assurance. Both share the same boxed thyroid C-cell warning class, the same pregnancy contraindication, and the same MEN-2 contraindication. See the FDA Zepbound prescribing information for current tirzepatide labeling, and Eli Lilly's TRIUMPH program page on ClinicalTrials.gov for active retatrutide trials.

References

Jastreboff AM, Kaplan LM, Frías JP, et al. 2023. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. PMID 37366315
Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PMID 35658024
Aronne LJ, Sattar N, Horn DB, et al. 2024. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. PMID 38078870
Aronne LJ, Horn DB, le Roux CW, et al. 2025. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PMID 40353578
Frias JP, Davies MJ, Rosenstock J, et al. 2021. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. PMID 34170647

Retatrutide — community signal

Recent posts and videos mentioning Retatrutide from the cron-ingested Reddit + X pipelines and the curated /experts directory. Not endorsement — directional context only.

Tirzepatide — community signal

Recent posts and videos mentioning Tirzepatide from the cron-ingested Reddit + X pipelines and the curated /experts directory. Not endorsement — directional context only.

Community Notes

0 approved · moderated

Structured notes from readers — context, citations, corrections, and first-hand experience. Every note is moderated before it appears. Notes do not replace medical review; they supplement it.

No approved notes yet.

Know something that should be on this page? A citation, clarification, or dispute? Sign in and submit the first note.

Submission interface coming in Phase 2. For now, notes are authored in Studio. See the Community Guidelines for moderation criteria.